American association of clinical endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis

Endocrine Practice

Volumn 7, Issue 4, 2001, Pages 294-312

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADVACAL; ALENDRONIC ACID; ALKA MINTS; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCI CHEW; CALCI MIX; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; GONADORELIN ANTAGONIST; HEPARIN; ONE A DAY; PHENOBARBITAL; PHENYTOIN; PIPERAZINE ESTRONE SULFATE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THYROID HORMONE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE RADIOGRAPHY; BONE TISSUE; BONE TURNOVER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIET THERAPY; DISEASE PREDISPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOCRINE DISEASE; EXERCISE; FALLING; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCIURIA; IMMOBILIZATION; KIDNEY TUBULE ACIDOSIS; LIVER DISEASE; MASTOCYTOSIS; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MEDICAL SPECIALIST; MYELOMA; NEOPLASM; NUTRITIONAL DISORDER; ORGAN TRANSPLANTATION; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; RISK FACTOR; SCORING SYSTEM; SMOKING CESSATION; THALASSEMIA; TREATMENT INDICATION; UNITED STATES; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION;

EID: 0034900335     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Consensus Development Conference on Osteoporosis, Hong Kong, April 1-2, 1993
2. Development of clinical practice guidelines for prevention and treatment of osteoporosis
3. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis
4. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: Technical aspects
5. Relationship between exercise and bone mineral density among over 5,000 women aged 40 years and above
6. Therapy for fracture prevention
7. Evidence-based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomised clinical trials
8. The effect of exercise training programs on bone mass: A meta-analysis of published controlled trials in pre- and postmenopausal women
9. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean
10. Perimenopausal bone density screening-will it help prevent osteoporosis?
11. Axial bone mass in older women
12. Antifracture efficacy of antiresorptive agents are related to changes in bone density
13. Understanding the bone mass measurement act
14. Biochemical markers of bone turnover: Applications for osteoporosis
15. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability
16. Clinical use of biochemical markers of bone remodeling: Current status and future directions
17. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
18. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
19. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
20. Esophagitis associated with the use of alendronate
21. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
22. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women
23. Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial
24. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women
25. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
26. Prevention of nonvertebral fractures by alendronate: A meta-analysis
27. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
28. Upper gastrointestinal toxicity of alendronate
29. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
30. Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal
31. Alendronate-associated esophagitis: Endoscopic and pathologic features
32. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
33. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
34. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women
35. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women
36. The clinical tolerability profile of alendronate
37. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
38. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients
39. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
40. Effect of risedronate on the risk of hip fracture in elderly women
41. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
42. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial; European Corticosteroid-Induced Osteoporosis Treatment Study
43. Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis
44. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss
45. Role of oral pamidronate in preventing bone loss in postmenopausal women
46. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment
47. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis
48. Cyclical pamidronate infusions in postmenopausal osteoporosis
49. A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial
50. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss
51. Treatment of osteoporosis with bisphosphonates
52. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study
53. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women
54. Reduced mortality associated with long-term postmenopausal estrogen therapy
55. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages
56. Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study
57. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
58. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: A population-based 5-year randomized trial
59. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: A 5 year randomized trial
60. Prescribing hormone replacement therapy for menopausal symptoms
61. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial
62. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
63. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
64. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial; Multiple Outcomes of Raloxifene Evaluation
65. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
66. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
67. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
68. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study; a randomized, controlled trial
69. A prospective study of thiazide use and fractures in women
70. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized controlled trial
71. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists
72. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women
73. Effect of ipriflavone - A synthetic derivative of natural isoflavones - On bone mass loss in the early years after menopause
74. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
75. Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency
76. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
77. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone
78. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVO Study
79. Slow-release sodium fluoride in osteoporosis
80. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures
81. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis: A randomized, controlled trial
82. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures
83. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass
84. Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women
85. Vertebral fractures and mortality in older women: A prospective study
86. Influence of fracture criteria on the outcome of a randomized trial of therapy
87. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation